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For older patients with acute myeloid leukemia (AML), allogeneic hematopoietic cell transplantation (HCT)
provides the best chance of long-term survival. A formal comparison between matched sibling (SIB), unre-
lated donor (URD), or umbilical cord blood (UCB) transplantation has not yet been reported in this setting. We
compared reduced-intensity conditioning HCT in 197 consecutive patients 50 years and older with AML in
complete remission from SIB (n ¼ 82), URD (n ¼ 35), or UCB (n ¼ 80) transplantation. The 3-year cumulative
incidences of transplantation-related mortality were 18%, 14%, and 24% with SIB, URD, and UCB trans-
plantation, respectively (P ¼ .22). The 3-year leukemia-free survival rates were 48%, 57%, and 33% with SIB,
URD, and UCB transplantation, respectively (P ¼ .009). In multivariate analysis, poor-risk cytogenetics was
associated with relapse (hazard ratio, 1.7 [95% conﬁdence interval, 1.0 to 3.0]; P ¼ .04) and worse leukemia-
free survival (hazard ratio, 1.6 [95% conﬁdence interval, 1.0 to 2.5]; P ¼ .03), whereas donor choice had no
signiﬁcant impact on overall survival (P ¼ .73). Adjusted 3-year overall survival rates were 55% with SIB, 45%
with URD, and 43% with UCB transplantation (P ¼ .26). Until prospective studies are completed, this study
supports the recommendation to consider SIB donor, URD, or UCB for HCT for older patients with AML in
complete remission.
 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.INTRODUCTION donor source for patients without an available SIB or URD
Acute myeloid leukemia (AML) occurs frequently in older
patients, with an overall poor prognosis [1]. Despite the
potential beneﬁt of intensiﬁed postremission treatments
developed in younger adult AML protocols, this does not
beneﬁt the older population [2]. For the older AML patient,
allogeneic hematopoietic cell transplantation (HCT) likely
provides the best chance of long-term survival [3,4]. HCT is
uncommonly used in this population, however, because of
the perceived higher risks of transplantation complications,
especially using unrelated donors (URDs) or umbilical cord
blood (UCB) donors [5]. A large analysis reported comparable
outcomes of HCT using reduced-intensity conditioning (RIC)
regimens using related donors or URDs among older patients
with AML andmyelodysplastic syndrome, indicating that age
per se is not a contraindication to HCT [6].
Because older patients less often have available healthy
HLA identical matched sibling (SIB) donors, alternative
donors may broaden access to HCT. Unrelated umbilical cord
blood (UCB) has been increasingly accepted as an alternativeedgments on page 1359.
requests: Dr. Régis Peffault de Latour,
ital Saint Louis, Paris, France.
latour@sls.aphp.fr (R. Peffault de Latour).
2013 American Society for Blood and Marrow
13.06.006[7-10]. The feasibility of UCB HCT for older patients with AML
or myelodysplastic syndrome has been suggested [11-13],
yet a formal comparison of these 3 graft options for older
patients with AML has not been reported. We present
comparative outcomes of reduced-intensity conditioning
(RIC) HCT for AML patients over age 50 years in complete
remission (CR) using SIB donors, URDs, or UCB donors.METHODS
Study Population
From January 2000 to December 2010, 197 consecutive patients with
AML in complete remission age 50 years or more (median age, 59; range, 50
to 74) received RIC and allogeneic HCT in 3 institutions (University of
Minnesota, Hospital Saint Louis Paris, and University Hospital of Nantes)
either from SIB donors (n¼ 82), URDs (n¼ 35), or UCB (n¼ 80). Disease risks
were deﬁned as favorable, intermediate, or poor for AML [14]. Karnofsky
performance status was recorded before HCT. All patients were treated on
protocols approved by the institutional review board of each hospital.
Informed consent was obtained in accordance with the Declaration of
Helsinki.
Data were collected prospectively, as Hospital Saint Louis Paris and
University Hospital of Nantes belong to the European Group for Blood and
Marrow Transplantation (EBMT) and sharing ProMISe (Project Manager
Internet Server), which is the central data management system used by the
EBMT. Both centers prospectively enter patient information and retrieve
data directly over a secure Internet connection. At the University of Min-
nesota, data on all patients undergoing transplantation are prospectively
collected in the institutional bone marrow transplantation researchTransplantation. Published by Elsevier Inc. All rights reserved.
Table 1
Patient Characteristics According to Type of Donor
Variable SIB URD UCB P Value
No. of patients 82 35 80
Age at transplantation, median (range), yr 58 (50-74) 59 (50-74) 59 (50-71) .89
50-59 median (%) 52 (63) 18 (51) 44 (55)
60-75 median (%) 30 (37) 17 (49) 36 (45)
Male gender, no. (%) 47 (57) 19 (54) 44 (55) .95
Karnofsky score before transplant, no. (%) .043
<90% 8 (10) 1 (3) 15 (19)
90%-100% 68 (83) 31 (89) 59 (74)
Not reported 6 (7) 3 (9) 6 (8)
Cytogenetic risk group, no. (%) .099
Good 4 (5) 4 (11) 3 (4)
Intermediate 52 (63) 23 (66) 39 (49)
Poor 18 (22) 6 (17) 27 (34)
Unknown 8 (10) 2 (6) 11 (14)
Disease status at transplant, no. (%) .26
CR1 59 (72) 26 (74) 49 (61)
CR  2 23 (28) 9 (26) 31 (39)
Interval from diagnosis to HCT, median (range), mo 6 (3-72) 7 (4-58) 6 (2-70) .22
Less than 6 mo N (%) 40 (49) 10 (29) 42 (52)
6-12 mo N (%) 24 (29) 17 (49) 11 (14)
More than 12 mo N (%) 18 (22) 8 (23) 27 (34)
Median (range) for CR1 patients, mo 5 (3-9) 6 (4-9) 4 (2-24) <.0001
Median (range) for CR 2 patients, mo 25 (6-72) 21 (7-58) 21 (4-70) .78
Donor/recipient gender matching, no. (%) .0001
Female/female 20 (24) 7 (20) 14 (18)
Female/male 16 (20) 6 (17) 35 (44)
Male/female 15 (18) 8 (23) 22 (28)
Male/male 31 (38) 13 (37) 9 (11)
Unknown 0 (0) 1 (3) 0 (0)
Donor/recipient cytomegalovirus serostatus, no. (%) <.0001
Negative/negative 15 (18) 11 (31) 31 (39)
Negative/positive 15 (18) 4 (11) 46 (57)
Positive/negative 10 (12) 5 (14) 0 (0)
Positive/positive 31 (38) 7 (20) 0 (0)
Unknown 11 (13) 8 (23) 3 (4)
Conditioning regimen, no. (%) <.0001
FLU/TBI  other 20 (24) 4 (11) 80 (100)
BU/FLU 35 (43) 25 (71) 0 (0)
CY/TBI 23 (28) 1 (3) 0 (0)
Other 3 (4) 4 (11) 0 (0)
Unknown 1 (1) 1 (3) 0 (0)
ATG, no. (%) 25 (30) 30 (86) 23 (29) <.0001
GVHD prophylaxis, no. (%) <.0001
CsA  CS or MTX 23 (28) 15 (43) 1 (1)
CsA þ MMF  other 59 (72) 19 (54) 77 (96)
Other 0 (0) 0 (0) 1 (1)
Unknown 0 (0) 1 (3) 1 (1)
Graft composition
Total nucleated cells, median (IQR)  108/kg 10 (8-14) 11 (7-12) .4 (.3-.4) <.0001
CD34þ cells, median (IQR)  106/kg 6 (5-8) 8 (6-10) .5 (.4-.7) <.0001
Yr of transplantation, no. (%) .002
2000-2005 26 (32) 1 (3) 25 (31)
2006-2010 56 (68) 34 (97) 55 (69)
Center, no. (%) <.0001
University of Minnesota 31 (38) 3 (9) 74 (92)
University Hospital of Nantes 21 (26) 18 (51) 5 (6)
Hospital Saint Louis Paris 30 (37) 14 (40) 1 (1)
FLU indicates ﬂudarabine; BU, busulfan; CY, cyclophosphamide; CsA, cyclosporine; CS, corticosteroids; MTX, methotrexate; MMF, mycophenolate mofetil; IQR,
interquartile range.
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retrieved and merged for this combined analysis.HLA Typing, Matching, and Donor Selection Policy
All related donors were HLA-matched SIBs based on family studies.
Histocompatibility testing and selection of URDs are described in detail
elsewhere [15]. Recipients and URDs were deﬁned as matched (“8/8”) if
HLA-A, -C, -B, and -DRB1 were identical at the molecular level. All URDs but
1 (7/8) were 8/8 allele matched. SIBs and URDs all received ﬁlgrastim-
mobilized peripheral blood grafts. UCB units were required to be matched
at greater than 4 of 6 HLA antigens based on antigen-level HLA-A and -Btyping and allele-level HLA-DRB1 typing. Matching at HLA-C, -DQ, and -DP
was not considered.
Over the duration of the study, UCB units were required to have
a minimum cryopreserved total nucleated cell dose of 2.0  107/kg. The
target cell dosewas greater than or equal to 3.0107 total nucleated cells/kg,
however, resulting in the selection of a second partially HLA-matched UCB
unit if available. In those for whom a second UCB unit could be identiﬁed, the
second unit also had a minimum of 4 of 6 antigens matched with the ﬁrst
unit [10,16]. Seventy UCB HCT recipients (88%) received 2 UCB units, and 75
(94%) received at least 1 to 2 HLA-mismatched units. In the absence of
a matched SIB donor, UCB grafts were the ﬁrst-choice option for the Min-
nesota group based on experience and research priorities. In the same
Table 2
Univariate Analysis for Outcomes Post-HCT
Outcome SIB URD UCB P Value
Neutrophil engraftment .0003*
At 28 d 99% (88-100)# 94% (76-99) 85% (75-91)
At 60 d 100% (96-100) 97% (70-100) 96% (88-99)
Acute GVHD grades II-IV .18*
At 100 d 29% (19-39) 38% (22-54) 39% (28-50)
Acute GVHD grades III-IV .59*
At 100 d 10% (5-18) 15% (5-29) 14% (8-23)
Chronic GVHD .14y
At 1 yr 34% (24-44) 37% (21-53) 18% (10-27)
At 3 yr 43% (31-54) 41% (24-57) 23% (15-34)
* Gray’s test.
y Score test in a cause-speciﬁc proportional hazards model.
# Results are presented as % (range).
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preferentially selected URDs.
Treatment
All patients received an RIC regimen [17] according to each institution’s
policy. Hospital Saint Louis Paris and University Hospital of Nantes mostly
used for SIBs and URDs the combination of ﬂudarabine (30 mg/m2 i.v. daily
from days 5 through 1), busulfan (3.2 mg/kg i.v. twice daily on days 4
and 3), and rabbit antithymocyte globulin (ATG; 5 mg/kg for SIBs and
10 mg/kg for URDs on days 2 and 1). The University of Minnesota RIC
regimen consisted of cyclophosphamide (50 mg/kg i.v. on day 6), ﬂudar-
abine (40 mg/m2 i.v. daily from days 6 through 2), and total body
irradiation (TBI; 200 cGy on day 1). All patients received prophylaxis for
graft-versus-host disease (GVHD) with cyclosporine (from days3 toþ180),
and most also received mycophenolate mofetil (from days 3 to þ30).
Hospital Saint-Louis Paris and the University Hospital of Nantes
practice the same patient daily care routine as recommended by the Joint
Accreditation CommitteeeInternational Society for Cellular Therapy and
EBMT, which is similar to the University of Minnesota group. Patients
were hospitalized in single rooms ventilated with high-efﬁciency partic-
ulate air ﬁltration systems. Patients received prophylactic low-dose
acyclovir until day 100. Documented cytomegalovirus reactivation or
infection demonstrated by antigenemia or DNA PCR testing after trans-
plantation was treated with therapeutic doses of ganciclovir or foscarnet
(foscavir) (depending on cytopenias and kidney function). Broad-
spectrum antibiotics were administered for fever during neutropenia,
and antifungal coverage was added for persistent fever unresponsive to
antibiotic therapy. All patients received ﬂuconazole or voriconazole for
prophylaxis of fungal infections for 100 days and trimethoprim-
sulfamethoxazole for prophylaxis of Pneumocystis juroveci after engraft-
ment for 12 months after transplantation.
Statistical Analysis
The primary endpoint was probability of overall survival (OS).
Secondary study endpoints included probability of neutrophil recovery
(absolute neutrophil count  500/mL for at least 3 days), platelet recovery
(platelets 20,000/mL for at least 3 days), leukemia-free survival (LFS),
cumulative incidences of acute and chronic GVHD, relapse, and treatment-
related mortality (TRM). LFS was deﬁned as survival in continuous
complete remission (CR). TRM was deﬁned as death after HCT without
leukemia relapse. Standard clinical criteria were used to diagnose and grade
GVHD [18,19].
Time-to-event outcomes were counted from the date of transplantation
to the date of event or date of last follow-up. Engraftment and acute GVHD
were arbitrarily censored at 100 days, and other outcomes were censored at
36 months, given the study follow-up. Death was considered as a competing
risk in analyses of engraftment and acute and chronic GVHD. TRM and
relapse were considered to be mutually competing risks. OS and LFS func-
tions were estimated using Kaplan-Meier product-limit estimator. For
competing risk analyses, cumulative incidence functions (CIFs) were esti-
mated using the usual methodology [20].
Characteristics of patients were compared according to donor using
Kruskal-Wallis tests, Wilcoxon rank-sum tests, and Fisher’ exact tests.
Factors associated with outcomes were analyzed using Gray’s tests (acute
GVHD), proportional hazards models for the cause-speciﬁc hazard [21]
(relapse and TRM), and Cox proportional hazards models (LFS and OS).
Covariates used for adjustment were age (<60 or 60 years), poor cytoge-
netic risk, disease status at transplantation, interval from diagnosis to HCT
(<6 or 6 months for patients that underwent transplantation in CR1),female donor to male recipient, TBI, and ATG. The proportional hazards
assumption was checked by examination of Schoenfeld residuals and
Grambsch and Therneau’s lack-of-ﬁt test [22]. Random center effects were
also added to themodels and tested usingmixed-effects Coxmodels [23]. All
tests were 2-sided, and P  .05 was considered as indicating signiﬁcant
association. Analyses were performed using the R statistical software,
version 2.15.0 (R Development Core Team, Vienna, Austria).
RESULTS
Patient Characteristics
Patient characteristics were similar between the 3 groups
for age, gender, CR stage, and time from diagnosis to HCT
(Table 1). UCB recipients had more frequent high-risk
features, including Karnofsky performance score <90% (19%
versus 10% SIB and 3% URD; P ¼ .04), female donor to male
recipient (44% versus 20% SIB and 17% URD; P ¼ .04), and
a trend for more poor risk cytogenetics (UCB 34%, SIB 22%,
URD 17%; P ¼ .06). Conditioning regimens also differed
between the 3 groups. Fludarabine and low-dose TBI were
more frequent in UCB (100% versus 24% in SIB and 11% in
URD; P < .0001), ﬂudarabine and busulfan were more
frequent in URD (71% versus 43% SIB and 0 UCB, P < .0001),
and cyclophosphamide plus low-dose TBI were more
frequent in SIB (28% versus 3% URD and 0 UCB, P < .0001).
ATG was more frequently used in URD (86% versus 29% SIB
and 29% UCB; P < .0001). UCB transplantation was almost
exclusively performed at the University of Minnesota,
whereas data on URDs were from Hospital Saint Louis Paris
and University Hospital of Nantes.
Engraftment and Acute and Chronic GVHD
The median follow-up was 39 months (range, 2 to 104;
42months for SIB [range, 2 to 98], 25 months for URD [range,
12 to 61], and 51 months for UCB [range, 12 to 104]).
Neutrophil recovery was better with SIB and URD compared
with UCB (99% [95% conﬁdence interval [CI], 88% to 100%],
94% [95% CI, 76% to 99%], and 85% [95% CI, 75% to 91%],
respectively; P ¼ .0003) at day 28. Platelet recovery was
better for URD and lowest with UCB (94% [95% CI, 75% to 99%]
with URD, 86% [95% CI, 76% to 92%] with SIB, and 73% [95% CI,
61% to 81%] with UCB; P < .0001) at 3 months. We did not
observe graft rejection. Cumulative incidences for acute and
chronic GVHD were similar between SIB, URD, and UCB
(Table 2).
TRM, Relapse, LFS, and OS
During follow-up, 94 patients died. The 3-year CIF of TRM
was 18% (95% CI, 10 to 28), 14% (95% CI, 5 to 28), and 24% (95%
CI, 15 to 34) with SIB, URD, and UCB, respectively (P ¼ .22).
The 3-year CIF of relapse was 33% (95% CI, 23 to 44), 29% (95%
Table 3
Multivariate Analysis for OS, LFS, Relapse, and TRM
Variable OS LFS Relapse TRM
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Donor group
SIB 1 d 1 d 1 d 1
URD 1.16 (.51-2.65) .73 1.26 (.58-2.73) .56 1.34 (.52-3.43) .54 1.55 (.39-6.16) .53
UCB 1.23 (.72-2.12) .45 1.23 (.72-2.08) .45 1.51 (.76-2.99) .24 .95 (.40-2.24) .90
Age at transplantation, yr
50-59 1 d 1 d 1 d 1
60-75 1.12 (.72-1.74) .62 1.00 (.65-1.52) .99 .71 (.41-1.21) .21 1.89 (.89-4.02) .098
Cytogenetic risk
Good/intermediate 1 d 1 d 1 d 1
Poor 1.56 (.99-2.47) .057 1.61 (1.04-2.50) .035 1.74 (1.02-2.98) .041 1.27 (.57-2.81) .56
Disease status/interval to HCT
CR1/<6 mo 1 d 1 d 1 d 1
CR1/6 mo .73 (.38-1.42) .36 .69 (.36-1.29) .24 .52 (.23-1.18) .12 1.10 (.40-3.03) .85
CR  2 1.19 (.73-1.95) .48 1.19 (.74-1.90) .47 1.04 (.59-1.82) .90 1.62 (.68-3.83) .27
Female donor to male recipient
No 1 d 1 d 1 d 1
Yes .92 (.57-1.49) .73 .99 (.63-1.58) .98 .94 (.53-1.66) .82 1.11 (.49-2.51) .81
TBI, 2 Gy
No 1 d 1 d 1 d 1
Yes 1.82 (.87-3.82) .11 1.82 (.91-3.66) .092 1.03 (.45-2.36) .95 7.31 (1.78-30.1) .006
ATG
No 1 d 1 d 1 d 1
Yes 1.05 (.61-1.81) .87 1.07 (.64-1.82) .79 .80 (.41-1.55) .50 1.82 (.77-4.28) .17
Figure 1. Adjusted OS curves in the 3 donor groups.
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UCB, respectively (P ¼ .041). Consequently, the 3-year LFS
rate was 48% (95% CI, 38 to 62), 57% (95% CI, 42 to 78), and
33% (95% CI, 23 to 45) with SIB, URD, and UCB, respectively
(P ¼ .009). In adjusted multivariate analysis, however, poor-
risk cytogenetics was associated with a signiﬁcantly higher
risk of relapse (hazard ratio [HR], 1.74 [95% CI, 1.02 to 2.98];
P ¼ .041), worse LFS (HR, 1.61 [95% CI, 1.04 to 2.50]; P ¼ .035),
and a trend for worse OS (HR, 1.56 [95% CI, .99 to 2.47];
P ¼ .057) (Table 3). Notably, we found no signiﬁcant differ-
ences in OS between age subgroups (age 60 þ HR, 1.12 [95%
CI, .72 to 1.74] versus age 50 to 60) or remission status (CR2
or 3 HR, 1.31 [95% CI, .83 to 2.07] versus CR1) and a similar
rate of adjusted TRM between the 3 sources of stem cells.
Outcomes including OS, relapse rate, and LFS (not shown)
using each donor source were similar (OS: UCB HR, 1.23 [95%
CI, .72 to 2.12]; P ¼ .45; URD HR, 1.16 [95% CI, .51 to 2.65],
P ¼ .73 versus SIB; relapse rate: UCB HR, 1.51 [95% CI, .76 to
2.99], P ¼ .24; URD HR, 1.34 [95% CI, .52 to 3.43]; P ¼ .54
versus SIB). Adjusted 3-year OS rate was 51% (95% CI, 38 to
63) with SIB, 53% (95% CI, 28 to 78) with URD, and 45% (95%
CI, 31 to 58) with UCB (P ¼ .73) (Figure 1). We found no
independent center effect that might have biased our
comparison of the 3 sources of stem cells.
DISCUSSION
The aim of this analysis was to study the impact of donor
type on survival after HCT in a well-deﬁned cohort of 197
consecutive patients age 50 years or more with AML in CR. In
our analysis, adjusted OS and LFS rates were not different
between SIB, URD, and UCB HCT. This is important news
because a matched SIB donor can only be found for 30% of
patients, and many physicians hesitate to refer elderly
patients for URD HCT, as shown in a feasibility analysis of RIC
regimens for patients older than 50 years with AML [5].
TRM is classically the main argument not to proceed to
HCT from a URD (especially from cord blood) in this older
patient population. Engraftment was delayed as previously
reported with UCB [10,12], but engraftment incidence wassimilar to SIB and URD HCT by day 60. Acute and chronic
GVHD rates were also similar to 3-year TRM. In a study from
the Center for International Blood and Marrow Trans-
plantation Research, TRM was greater using UCB compared
with that after URD peripheral blood, but that study included
all adult patients with acute leukemias, not just older adults
with AML in CR receiving an RIC regimen [24].
In patients with AML, the other leading cause of treat-
ment failure is relapse [25-27]. In our study, there was
a trend for higher 3-year CIF of relapse with UCB, and the
univariate analysis showed a slightly lower 3-year LFS rate
after UCB HCT. However, the UCB group had more patients
with Karnofsky performance scores <90% and a trend for
worse cytogenetic risk. In adjusted multivariate analysis,
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nearly double risk of relapse, worse LFS rates, and a trend for
worse OS. The higher relapse rate observed with UCB might
thus be related to the imbalance in cytogenetic risk between
the 3 groups. Notably, we found no signiﬁcant differences in
OS between age subgroups (age 60 þ versus age 50 to 60) or
remission status (CR2 or 3 versus CR1). The selection of
higher-risk patients (including poor-risk cytogenetics) for
alternative donor HCT during CR1 may thus explain, at least
in part, the latter ﬁnding. Importantly, adjusted 3-year OS
was similar using SIB, URD, or UCB HCT.
These results should be consideredwith caution, however,
because the conditioning regimen varied somewhat between
the centers. Moreover, patients that underwent trans-
plantation with a URD more often received ATG in the
conditioning regimen, which could also inﬂuence our re-
ported outcomes. The use of TBI-containing conditioningwas
associated with a nonsigniﬁcant, but somewhat worse OS
rate in recipients of matched related donor and URD grafts,
whereas all patients with UCB grafts received low-dose TBI.
Although the association of a higher risk of relapse with low-
dose TBI is in accordance with what has already been pub-
lished [28], the association with a higher rate of TRM is
surprising. We believe this analysis is potentially related to
confounding factors (all patients who underwent cord
transplantations received TBI 2 Gy, whereas this regimenwas
used only in half of the patients who received an SIB trans-
plantation). The retrospective setting of our study as well as
the current results may suggest that the use of non-TBI
regimens for SIB and URD grafts need to reassessed, which
is best done in prospective randomized trials.
This study has validity in thatwe included consecutive and
prospective data from 3 experienced centers, each with
consistent strategies for donor selection for older AML
patients and no SIB donors. At the University of Minnesota,
based on experience and research priorities, UCB grafts were
the ﬁrst-choice option, whereas the Hospital Saint Louis Paris
and the University Hospital of Nantes preferentially selected
URD. Each center used consistent and similar conditioning
regimens, GVHD prophylaxis, and supportive care. We also
found no independent center effect that might have biased
our direct comparison of the 3 sources of stem cells. These
consistent and homogeneous treatment strategies provide
insights beyond registry studies where heterogeneity might
confound some comparisons. We cannot exclude a possible
bias due to the almost exclusive use of UCB grafts at the
University of Minnesota versus URD at Hospital Saint Louis
Paris and the University Hospital of Nantes, however, and that
40% of the patients with UCB underwent transplantation in
CR2 to 3. Moreover, our study may be limited by its retro-
spective nature and the modest number of patients, yielding
insufﬁcient power to detect small but clinically important
differences in outcomes. In particular, the population of URD
transplantation is under-represented. Enrollment bias might
result in only patients with no or few comorbidities referred
for URD transplantations or only those with the highest risk
being referred for transplantation in an early CR. To minimize
this bias, we adjusted the statistical analysis for baseline
differences in the various patient cohorts. It is desirable to
study the impact of donor type in disease-speciﬁc prospective
clinical trials, and we may expect additional information on
the impact of donor type to come from prospective studies
being run by the AML study groups.
Overall, these data suggest comparable outcome when
using SIB donors, URDs, or UCB donors in patients age50 years and older with AML in CR. Poor cytogenetic risk was
the dominant prognostic factor, inﬂuencing relapse and LFS
rates with a trend for worse OS rates. Despite the method-
ological restrictions of a retrospective analysis, our data
support the recommendation to consider SIB, URD, or UCB
for HCT for older patients with AML in CR. The number of
older patients with AML who beneﬁt from a postremission
therapy with allogeneic HCT may thereby increase.
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